研究者詳細 - 國定　俊之

論文 - 國定　俊之

分割表示 556 件中 181 - 200 件目／全件表示 >>

骨腫瘍切除後の配向連通孔構造を持つβ-TCPによる再建

近藤彩奈, 中田英二, 国定俊之, 藤原智洋, たき平将太, 近藤宏也, 佐藤浩平, 畑利彰, 片山晴喜, 尾崎敏文

移植 56 ( 4 ) 456 - 456 2022年2月

Soft-tissue sarcoma in adolescents and young adults 査読

Toshiyuki Kunisada, Eiji Nakata, Tomohiro Fujiwara, Ako Hosono, Shota Takihira, Hiroya Kondo, Toshifumi Ozaki

International Journal of Clinical Oncology 2022年1月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Springer Science and Business Media LLC

Soft-tissue sarcoma is a rare cancer that accounts for approximately 1% of all malignant tumors. Although they occur in various age groups, soft-tissue sarcomas account for 8% of all malignant tumors developing in adolescents and young adults, suggesting that they are not rare in this age group. This study aimed to evaluate the clinical and pathological characteristics of soft-tissue sarcoma in adolescents and young adults. According to the Bone and Soft-Tissue Tumor Registry in Japan, myxoid liposarcoma is the most common type of soft-tissue sarcoma found in adolescents and young adults; alveolar soft part sarcoma, extraskeletal Ewing sarcoma, epithelioid sarcoma, clear cell sarcoma and synovial sarcoma occur predominantly in this age group among soft-tissue sarcomas. The analysis based on this registry demonstrated that age was not a prognostic factor for poor survival of soft-tissue sarcoma, although the prognosis in adolescents and young adults was better than that in older patients in the US and Scandinavia. Adolescent and young adult patients with soft-tissue sarcoma have age-specific problems, and a multidisciplinary approach to physical, psychological, and social issues is necessary to improve the management of these young patients both during and after treatment.

DOI： 10.1007/s10147-022-02119-7

PubMed

researchmap

その他リンク： https://link.springer.com/article/10.1007/s10147-022-02119-7/fulltext.html

What are the Results of Resection of Forearm Soft Tissue Sarcoma?

Eiji Nakata, Tomohiro Fujiwara, Toshiyuki Kunisada, Ryuichi Nakahara, Toshiyuki Watanabe, Toshifumi Ozaki

2021年11月

出版者・発行元：Research Square Platform LLC

Abstract

Only few reports have assessed the characteristics and oncological and functional outcomes of forearm soft tissue sarcomas (STS). Then, we aimed to investigate the clinical features and survival-related factors for forearm STS who underwent surgical excision at our institution. There were 38 patients. Fourteen patients (41%) were referred to our institution after an unplanned excision and tumor size and grade were significantly associated with the receipt of it. The postoperative median Musculoskeletal Tumor Society rating scale (MSTS) score was 28. Bone resection or major nerve palsy was the only factor influencing the postoperative MSTS score (P < 0.001). There was no significant difference in MSTS scores according to the reconstruction procedures (the use of flap or tendon reconstruction). The 5-year local recurrence-free survival (LRFS) rate was 86%. Univariate analysis revealed that the histological diagnosis of myxofibrosarcoma was the only factor that influenced LRFS (P = 0.047). The 5-year metastasis-free survival rate was 77%. The 5-year overall survival (OS) rate was 94%. Age was the only factor that influenced OS (P = 0.01). In conclusion, reconstruction of the skin and tendon can compensate for function. Careful follow-up is important, especially in patients with myxofibrosarcoma, due to its likelihood of local recurrence.

DOI： 10.21203/rs.3.rs-1028963/v1

researchmap

その他リンク： https://www.researchsquare.com/article/rs-1028963/v1.html

良性腫瘍に対する低侵襲治療類骨骨種に対するRFA

冨田晃司, 馬越紀行, 宇賀麻由, 藤原智洋, 松井裕輔, 中田英二, 生口俊浩, 国定俊之, 平木隆夫, 尾崎敏文

日本小児整形外科学会雑誌 30 ( 3 ) S39 - S39 2021年11月

良性腫瘍に対する低侵襲治療術中CTナビゲーションを用いた類骨骨腫に対する低侵襲手術

藤原智洋, 国定俊之, 中田英二, 尾崎敏文

日本小児整形外科学会雑誌 30 ( 3 ) S38 - S38 2021年11月

【脊椎転移の治療最前線】脊椎転移に対する放射線治療の有用性

中田英二, 国定俊之, 藤原智洋, 杉原進介, 明崎禎輝, 金重総一郎, 尾崎敏文

臨床整形外科 56 ( 10 ) 1249 - 1256 2021年10月

記述言語：日本語出版者・発行元：(株)医学書院

＜文献概要＞脊椎転移による痛みに対しては,麻痺がない場合は放射線治療(RT)単独で早期に除痛が得られ,経時的に骨形成を認める場合が多い.標準的なRTは前後対向2門照射を用いた通常照射(分割照射:30Gy/10回)であるが,予後不良(3〜6ヵ月以内)であれば8Gy単回照射で十分である.麻痺を認める場合は除圧術とRTの併用を検討すべきである.最近,体幹部定位放射線治療の有用性が報告されているが,治療計画に時間を要するなどの欠点がある.なお,脊椎転移を有する患者に背部痛が出現した場合,脊椎転移による麻痺リスクを考慮し,早急に画像検査を行うべきである(red flag).

researchmap

【脊椎転移の治療最前線】脊椎転移に対する放射線治療の有用性

中田英二, 国定俊之, 藤原智洋, 杉原進介, 明崎禎輝, 金重総一郎, 尾崎敏文

臨床整形外科 56 ( 10 ) 1249 - 1256 2021年10月

記述言語：日本語出版者・発行元：(株)医学書院

researchmap

術前がん患者におけるがんロコモ・サルコペニアの有病率

堅山佳美, 中田英二, 濱田全紀, 国定俊之, 藤原智洋, 千田益生, 尾崎敏文

中国・四国整形外科学会雑誌 33 ( 3 ) 324 - 324 2021年10月

Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression. 査読国際誌

Kazuhisa Sugiu, Hiroshi Tazawa, Joe Hasei, Yasuaki Yamakawa, Toshinori Omori, Tadashi Komatsubara, Yusuke Mochizuki, Hiroya Kondo, Shuhei Osaki, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Koji Ueda, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara

Cancer chemotherapy and pharmacology 88 ( 3 ) 513 - 524 2021年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Osteosarcoma (OS) is a malignant bone tumor primarily affecting children and adolescents. The prognosis of chemotherapy-refractory OS patients is poor. We developed a tumor suppressor p53-expressing oncolytic adenovirus (OBP-702) that exhibits antitumor effects against human OS cells. Here, we demonstrate the chemosensitizing effect of OBP-702 in human OS cells. MATERIALS AND METHODS: The in vitro and in vivo antitumor activities of doxorubicin (DOX) and OBP-702 were assessed using parental and DOX-resistant OS cells (U2OS, MNNG/HOS) and a DOX-resistant MNNG/HOS xenograft tumor model. RESULTS: DOX-resistant OS cells exhibited high multidrug resistant 1 (MDR1) expression, which was suppressed by OBP-702 or MDR1 siRNA, resulting in enhanced DOX-induced apoptosis. Compared to monotherapy, OBP-702 and DOX combination therapy significantly suppressed tumor growth in the DOX-resistant MNNG/HOS xenograft tumor model. CONCLUSION: Our results suggest that MDR1 is an attractive therapeutic target for chemoresistant OS. Tumor-specific virotherapy is thus a promising strategy for reversing chemoresistance in OS patients via suppression of MDR1 expression.

DOI： 10.1007/s00280-021-04310-5

PubMed

researchmap

肉腫におけるがん遺伝子パネルによる融合遺伝子の検出

中田英二, 国定俊之, 藤原智洋, 遠西大輔, 冨田秀太, 尾崎敏文

中部日本整形外科災害外科学会雑誌 64 ( 秋季学会 ) 107 - 107 2021年9月